Muraglitazar
Muraglitazar is a PPAR α/γ dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC50 = 320 nM) and PPARγ (EC50 = 110 nM) [1].
Product Specifications
CAS Number
331741-94-7
Product Name Alternative
BMS-298585
UNSPSC
12352005
Hazard Statement
H315, H319, H335, H402
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/muraglitazar.html
Purity
98.38
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(O)CN(C(OC1=CC=C(OC)C=C1)=O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2
Molecular Formula
C29H28N2O7
Molecular Weight
516.54
Precautions
H315, H319, H335, H402
References & Citations
[1]Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27 (8) :1181-1195. |[2]Cox SL. Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Drugs Today (Barc) . 2005;41 (9) :579-587.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15247789 1 Vial
Lentiviral mouse Dpp9 shRNA (UAS) - Lentiviral mouse Dpp9 shRNA (UAS, RFP) plasmid
Sign In for Pricing
View Details